NMTR News and Press, 9 Meters Biopharma Inc. From 09/23/20

William Blair initiates coverage on $95M market cap 9 Meters Biotech (NMTR), saying its pipeline is a "blockbuster in the making."The current Phase 3 study of larazotide should show results in Q4 of 2021, says Blair, and, if positive, the company will file for conditional approval in the U.S....

RALEIGH, NC / ACCESSWIRE / August 31, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the formation of its scientific advisory board (SAB). The SAB comprises an esteemed group of six experts in the gastroe...

Gainers:  Allied Esports Entertainment (NASDAQ: AESE ) +94% . More news on: Allied Esports Entertainment Inc., Momenta Pharmaceuticals, Inc., Hudson Ltd., Stocks on the move, , Read more ...

9 Meters Biopharma (NASDAQ: NMTR ) is  up 35%  pre-market consecutively, as company discloses Director Sirgo Mark A bought 100k shares at $0.56/share, on August 17, 2020. More news on: 9 Meters Biopharma, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Are These Robinhood Penny Stocks On Your List This Week? If you’ve traded penny stocks this week, you know certain platforms haven’t been the easiest to work with. You might think that it’s Robinhood, again. But surprisingly enough, it’s one of the “classic...

4 Penny Stocks Experiencing Institutional & Insider Trading This Month What comes to mind when you hear “ penny stocks ” and “insider trading” in the same sentence? My guess is that if you’re a new trader, you get a little nervous. The only reason for tha...

Conference Call Scheduled for August 18, 2020 RALEIGH, NC / ACCESSWIRE / August 13, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate in the "Prepping ahead of Data" Conference Call Series hosted by hosted by Srikripa De...

9 Meters Biopharma (NASDAQ: NMTR ) : Q2 GAAP EPS of -$0.57. More news on: 9 Meters Biopharma, Inc., Earnings news and commentary, , Read more ...

- Initiates Phase 1b/2a clinical trial with a proprietary long-acting GLP-1 agonist, in short bowel syndrome; first patients dosed in July and top-line data expected by Q1 2021 - - Amended definition of primary endpoint for Phase 3 trial with larazotide in celiac disease, allowing reduc...

-William Blair Biotech Focus Conference - August 4 th - 6 th -BTIG Virtual Biotechnology Conference - August 10 th & 11 th RALEIGH, NC / ACCESSWIRE / August 4, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that management will participate in the following...